HID Provides Concurrent Drug Review to Ensure in Real Time that Drugs Are Prescribed Appropriately.

Utilizing Concurrent Review

The objective of a Concurrent Drug Review Program (CDRP) is to identify drugs or classes of drugs that should require a Prior Authorization (PA) before dispensing. This ensures that the drugs are being prescribed appropriately and in accordance with the FDA approved product labeling. This program can also ascertain that the patient for whom the drugs are being prescribed has tried and failed other alternative therapies that can be used first according to evidence based rules.

Some potential target drugs or drugs classes for the CDRP

Concurrent review is based on specific criteria developed for each drug or drug class in accordance with the FDA approved indications for that drug or drug class. The Medicaid P&T committee approves all criteria.

Drugs considered for the CDRP are usually those drugs which have a potential for abuse, misuse, or inappropriate use in prescribing and/or dispensing patterns. Whole classes of drugs are on PA list rather than only one or two drugs of a class, as may be the case in a Preferred Drug List.

Mr. Steve Espy, R.Ph., (left) explaining the CDRP operation to Congressman Mike Rogers, R-Alabama.

Health Information Designs has active, efficient, Concurrent Drug Review Programs in Alabama and Mississippi. The Relational Claims Database allows HID to perform sophisticated analysis that identify the drug classes that would be most beneficial to place in the program. This program has saved our clients over $20,000,000 per year in the PPI drug class alone, with no discernible increase or shift in related medical costs.


Requiring Mandatory Use of Generics >